NCT04728893 2026-04-13
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
43 trialsNCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT06859424 2026-03-17
ACCELERATE
Center for International Blood and Marrow Transplant Research
Phase 2 Recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT03766763 2025-11-26
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT06812715 2025-08-06
PIPOZA
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT04515238 2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2 Active not recruiting
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed
NCT03804372 2025-02-27
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT04716075 2025-01-16
ACALLO
Polish Lymphoma Research Group
Phase 2 Completed
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT01500733 2024-09-19
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04605666 2024-08-20
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT01597219 2024-05-03
UK-Haplo
University College, London
Phase 2 Completed
NCT01145209 2023-11-28
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05082519 2023-10-26
IDEAL2
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Recruiting
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT03068416 2021-10-20
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Phase 2 Completed
NCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed
NCT01109069 2020-05-27
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 2 Completed
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01279252 2019-01-25
CLEAR
King's College Hospital NHS Trust
Phase 2 Completed
NCT00467961 2018-07-13
Stem Cell Transplantation for Patients With Cancers of the Blood
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01446900 2018-01-31
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
Phase 2 Terminated
NCT01077622 2017-05-30
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT02227108 2017-04-06
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
MedImmune LLC
Phase 2 Terminated
NCT00201721 2017-02-08
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT00751296 2016-06-16
Rev-CLL
University Health Network, Toronto
Phase 2 Terminated
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT00230282 2014-10-06
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Stanford University
Phase 2 Completed
NCT00349349 2014-06-04
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
GlaxoSmithKline
Phase 2 Completed
NCT00410163 2014-02-10
BIFROST
GlaxoSmithKline
Phase 2 Completed
NCT00504491 2011-12-30
R-CHOP
CABYC
Phase 2 Withdrawn
NCT01127542 2011-12-05
RESPeCT
The Christie NHS Foundation Trust
Phase 2 Terminated
NCT00558181 2010-02-23
LT-CLL-001
Vilnius University
Phase 2 Completed
NCT00292760 2009-12-16
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Royal Marsden NHS Foundation Trust
Phase 2 Completed
NCT00485966 2008-11-05
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Cylene Pharmaceuticals
Phase 2 Withdrawn
NCT00083473 2005-08-30
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
Titan Pharmaceuticals
Phase 2 Terminated